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Lipodystrophic syndromes are characterized by adipose tissue deﬁciency. Although
rare, they are of considerable interest as they, like obesity, typically lead to ectopic
lipid accumulation, dyslipidaemia and insulin resistant diabetes. In this paper we
describe a female patient with partial lipodystrophy (affecting limb, femorogluteal
and subcutaneous abdominal fat), white adipocytes with multiloculated lipid
droplets and insulin-resistant diabetes, who was found to be homozygous for a
prematuretruncationmutationinthelipiddropletproteincelldeath-inducingDffa-
like effector C (CIDEC) (E186X). Thetruncation disrupts thehighlyconserved CIDE-C
domainand the mutantproteinismistargetedandfailstoincreasethelipiddroplet
size in transfected cells. In mice, Cidec deﬁciency also reduces fat mass and induces
theformationofwhiteadipocyteswithmultilocularlipiddroplets,butincontrastto
our patient, Cidec null mice are protected against diet-induced obesity and insulin
resistance. In addition to describing a novel autosomal recessive form of familial
partial lipodystrophy, these observations also suggest that CIDEC is required for
unilocular lipid droplet formation and optimal energy storage in human fat.
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White adipose tissue (WAT) is essential for efﬁcient energy
(lipid) storage and release (Frayn, 2002). Although all
eukaryotic cells can store surplus energy as lipid droplets,
white adipocytes are uniquely adapted for the role. Several
lipid droplet associated proteins are speciﬁcally expressed in
white adipocytes, where they appear to be required for efﬁcient
lipid storage in and release from lipid droplets (Brasaemle et al,
2008;Traini&Jessup,2009).Storingtriglycerideandcholesterol
esters in a single large droplet reduces the lipid droplet
surface area available to lipolytic enzymes and optimizes the
storage capacity. The importance of fat in human metabolism is
highlighted by lipodystrophic syndromes, a heterogeneous
cluster of disorders characterized by a lack of WAT (Garg,
2004). Lipodystrophy is distinct from leanness, a state in
which ‘empty adipocytes’ can readily adapt to positive energy
balance. Instead, in lipodystrophic subjects, positive energy
balance leads to ectopic fat deposition in the liver and
other organs, insulin resistance and diabetes (Savage et al,
2007).
Lipodystrophies result from either the failure of adipocyte
development or premature destruction of adipocytes due to
genetic or immunological mechanisms (Garg, 2004). Recent
progress in understanding the genetic basis of several forms of
familial lipodystrophy has facilitated improved clinical diag-
nostic workup in patients with lipodystrophy as well as
providing novel insights into adipocyte biology. Biallelic loss
of function mutations in BSCL2, AGPAT2 or CAV1 account for
>90% of all cases of congenital generalized lipodystrophy,
whereas heterozygous mutations in LMNA and PPARG account
for >50% of all inherited cases of partial lipodystrophy (Garg &
Agarwal,2009).Rarehomozygousandcompoundheterozygous
mutations in LMNA and ZMPSTE24 have also been reported
and, in one family with partial lipodystrophy, a heterozygous
mutation in AKT2 was identiﬁed (George et al, 2004).
In this report, we describe a 14-year-old girl with a novel
subtype of partial lipodystrophy and ‘ketosis-prone’ insulin
resistant diabetes in association with a homozygous nonsense
mutation in CIDEC.
CASE HISTORY
A 19-year-old Ecuadorian girl was referred with partial
lipodystrophy and insulin resistant diabetes. She ﬁrst presented
at age 14 years with diabetic ketoacidosis (glucose 39.4mmol/
l; pH 7.25; bicarbonate 8.3mmol/l; strongly positive plasma
ketones). Clinically she was noted to have partial lipodystrophy
with muscular lower limbs and prominent acanthosis nigricans
(Fig 1A). This phenotype was reportedly present from early
childhood. Her body mass index (BMI) was 20.8kg/m
2 (BMI
Standard deviation score (SDS) þ0.52), blood pressure normal
(103/64mm Hg) and she had no signs of virilization or
dysmorphic features. Menarche had occurred at age 12 years
and menses were regular at presentation, but later became
irregular. ICA (islet cell antibodies), anti-GAD (GAD, glutamic
acid decarboxylase) and IA2 (protein tyrosine phosphatase-like
protein) antibodies were all negative and C-peptide levels were
elevated (1274pmol/l (174–960)). Interestingly, her lipid
proﬁle was normal at presentation (total cholesterol
4.3mmol/l, triglycerides 1.0mmol/l) but worsening dyslipi-
daemia developed within 18 months, to the extent that she
ultimately had pancreatitis secondary to hypertriglyceridaemia
(triglycerides 20.2mmol/l) and again presented with diabetic
ketoacidosis (pH 6.77; strongly positive ketones). Despite high
dose insulin therapy (1.6IU/kg/day), her glycemic control was
always poor (HbA1c 11.0–16.3%). She recently developed
microalbuminuria and hypertension (blood pressure 153/
96mm Hg).
Magnetic resonance imaging (MRI) of her fat distribution
conﬁrmed the virtual absence of lower limb and femorogluteal
fat pads and the preservation of visceral, neck and axilliary fat
(Fig 1B and Fig 1 of Supporting Information). Her total fat mass
was 20% by DXA (dual energy X-ray absorptiometry), which is
1SDbelowtheage-matchedmean.Plasmaleptin(2.8mg/l;BMI-
and gender-matched reference range 2.4–24.4mg/l) and adipo-
nectin levels (1.7mg/l; BMI- and gender-matched reference
range 2.6–12.6mg/l) were correspondingly low. She was also
noted to have striking hepatomegaly and hepatic steatosis on
MRI (Fig 1B).
RESULTS
Identification of a homozygous nonsense CIDEC mutation
The proband was wild type for all coding exons and splice
junctions of LMNA, PPARG, ZMPSTE24 and AKT2, so we went
on to sequence additional candidate genes for lipodystrophy.
We identiﬁed a homozygous transversion of guanine to thymine
at cDNA nucleotide position 556 in exon 6 of CIDEC, resulting in
the substitution of a premature stop codon (TAA) for a
glutamine codon (GAA) at codon 186 (ca 556G!T,
p.Glu186
  (E186X); Fig 1C). The mutation is predicted to truncate
the protein at amino acid 186, resulting in loss of a signiﬁcant
portion of the CIDE-C domain of CIDEC (Fig 1D). It was absent in
120 ethnically matched control alleles. The proband’s unaffected
mother was heterozygous for the CIDEC E186X variant. Her BMI,
fat distribution and biochemical parameters were all entirely
normal (Fig 1E). Two maternal half brothers were wild type for
this variant and manifested normal fat distribution and biochem-
istry. Theproband’sfatherwasnot availableforgenetic testing but
single nucleotide polymorphism (SNP) genotyping analysis of the
proband revealed a total genomic homozygosity value of 13.5%
which is consistent with parental consanguinity (A-M Patch,
unpublished observations; Woods et al, 2006). The mutation
containing the homozygous segment was found to be 19.03-Mb
long, spanning 3p26.3–3p24.3 delimited by the SNPs rs163577–
rs17070741.
Adipose tissue histology
Since CIDEC (mouse orthologue is known as Fsp27) is a lipid
droplet protein implicated in the formation of white adipocytes
with unilocular lipid droplets in mice (Nishino et al, 2008; Toh
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biopsy. The most striking ﬁnding in the tissue sample was the
presence of many adipocytes with multiple small lipid
droplets, each of which was strongly immunoreactive to
perilipin (so called ‘multilocular adipocytes’), rather than the
normal single large droplet (Fig 2A). The number of lipid
droplets per cell varied inversely with cell size (Fig 2B).
Unilocular adipocytes were similar in size to adipocytes from a
lean control (Fig 2 of Supporting Information). Immunohisto-
chemistry for UCP1 (uncoupling protein 1) was negative (data
not shown), suggesting that these were white-, not brown
adipocytes,but intensefocalcytochrome c immunoreactivityin
some cells with multilocular lipid droplets suggests that
mitochondrial mass is increased in at least some of the
proband’s adipocytes (Fig 2C). Electron microscopy (EM)
conﬁrmed the multilocular nature of lipid droplets in many
white adipocytes (Fig 2D) and the apparent focal increase in
mitochondrial density (Fig 2D). There was no evidence of
excess crown-like structures or inﬂammation in the adipose
tissue.
Although the ‘multilocular adipocytes’ seen in this patient are
not typical brown adipocytes, we wondered if these cellular
changes might alter the resting metabolic rate (RMR). The
proband’s RMR was signiﬁcantly increased when compared to
healthy controls. The elevation in RMR remained after
correction for lean body mass (Fig 3A of Supporting Informa-
tion) and for fat and lean mass (Fig 3B of Supporting
Information). Thyroid function tests and plasma metanephrine
concentrations were normal (data not shown).
Cellular characterization of the E186X CIDEC mutant
In order to examine the function of the mutant CIDEC protein,
we electroporated COS cells and 3T3L1 pre-adipocytes with N-
terminal green ﬂuorescent protein-tagged (GFP-tagged) human
CIDEC vectors. Although lipid droplet size was signiﬁcantly
increased in COS cells over expressing wild type CIDEC
compared to untransfected cells (Fig 3A), lipid droplet size
was not altered in cells over expressing the mutant protein at a
similar level (Fig 3A). Similar effects were observed in 3T3L1
pre-adipocytes (Fig 3B). Formal morphometric analysis con-
ﬁrmed these visual observations in both cell types (Fig 3C) and
suggested that the mutant protein is biologically inert, at least in
terms of the protein’s actions on lipid droplet size in cultured
cells. Overlay of the GFP and oil-red-O stained images shows
some co-localization of wild type CIDEC and lipid droplets
whereas this is not seen in cells expressing the truncated CIDEC
protein (Fig 3A,B). The fact that most of the WT CIDEC is not
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Figure 1. Identification of a homozygous premature stop
E186X CIDEC mutation in a patient with acanthosis nigricans
and partial lipodystrophy.
A. Photograph demonstrating axillary acanthosis
nigricans in the proband.
B. T1 weighted magnetic resonance image of the
proband indicating the paucity of leg-,
forearm-, femorogluteal- and subcutaneous abdominal
fat. Axilliary fat and neck fat are preserved. The liver is
significantly enlarged due to severe steatosis. She also
manifests prominent muscle bulk.
C. Wild type CIDEC, E186X CIDEC homozygous (Homo;
proband) and heterozygous (Het; proband’s mother)
mutant sequence traces. Homozygous transversion of
guanine to thymine at nucleotide position 556 in exon
6o fCIDEC, results in the substitution of a premature
stop codon (TAA) for glutamine (GAA) at codon 186.
D. Schematic representation of CIDEC showing the
position of the E186X premature stop mutation (red
line), resulting in loss of a significant portion of the
CIDE-C domain (grey) of CIDEC. The CIDE-N domain is
highlighted in black and amino acid numbers are
indicated below.
E. Proband’s family pedigree (squares represent male and
circles female family members). Below each symbol,
age (years) is given, followed by the BMI (kg/m
2),
fasting glucose (mmol/l), insulin (pmol/l), HOMA
(homeostasis model assessment value; %), triglycerides
(mmol/l), free fatty acids (mmol/l), leptin (mg/l) and
genotype, with N denoting the normal (wild type)
allele and M the mutant allele.
 BMI for children is given as BMI SDS.
Filled symbol represents the affected proband and
hatched symbol her heterozygous mother.
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need for other differentiation-dependent proteins present in
adipocytestofacilitateCIDEC localization tolipid droplets.Thus
we also assessed localization of the wild type and E186X CIDEC
mutant in transfected adipocytes (six days after initiating
differentiation). Whereas most of the wild type CIDEC is
localized around lipid droplets in these transfected adipocytes,
the CIDEC truncated mutant is not (Fig 4), suggesting that the C-
terminal part of CIDEC is required for lipid droplet localization.
DISCUSSION
In a patient with unexplained partial lipodystrophy, we
identiﬁed a homozygous premature stop mutation in CIDEC.
CIDEC/Fsp27 is a lipid droplet protein most highly expressed in
adipocytes where its expression is induced during adipocyte
differentiation (Keller et al, 2008; Puri et al, 2007). Fsp27
knockdown in 3T3L1 pre-adipocytes reduces triglyceride
accumulation and lipid droplet size, and increases lipid droplet
number and lipolysis (Keller et al, 2008; Nishino et al, 2008). In
keeping with these data, Fsp27 knockout (KO) mice manifest
reduced adipose tissue mass and white adipocytes with
multilocular lipid droplets (Nishino et al, 2008; Toh et al,
2008). CIDEC is expressed in human WAT where its mRNA level
is inversely correlated with fat mass, reduced by a very low
calorie diet (Magnusson et al, 2008), and lower in adipose tissue
from obese insulin resistant compared to equally obese insulin
sensitive subjects (Puri et al, 2008). The latter observation is
particularly interesting as it suggests that reduced CIDEC
expression may contribute to the pathogenesis of obesity-
induced insulin resistance.
The CIDEC E186X mutation disrupts the highly conserved
CIDE-C domain which is known to be required for the protein’s
function (Chen et al, 2000; Keller et al, 2008). Expressing the
N-terminal half of Fsp27 in ﬁbroblasts had no effect on lipid
droplet formation, whereas expression of the C-terminal CIDE-C
domain was sufﬁcient to stimulate lipid accumulation (Keller
et al, 2008). The homologous CIDE-C domain of Cideb is
required for phospholipid membrane targeting and appears to
be equally critical for its biological activity (Ye et al, 2009).
When expressed in COS cells or 3T3L1 pre-adipocytes, the
mutant CIDEC protein is mistargeted and has similar effects on
lipid droplet morphology to those of an empty vector, whereas
expression of wild type CIDEC signiﬁcantly enhanced the
volume of cellular lipid droplets. The truncated CIDEC protein is
also mistargeted in differentiated 3T3L1 adipocytes where the
bulk of wild type CIDEC localizes around lipid droplets. The
most striking ﬁnding in our patient was the presence of many
white adipocytes with multilocular lipid droplets and focal
increases in mitochondrial mass. These observations are
consistent with what was seen in Fsp27 knockdown cells and
in Fsp27 null mice (Nishino et al, 2008; Toh et al, 2008) but in
contrast to the KO mouse phenotype, these changes were
associated with an adverse lipodystrophic, rather than a healthy
lean, phenotype. The presence of severe dyslipidaemia, fatty
liver, low leptin and adiponectin levels, coupled with insulin
resistance and diabetes in the CIDEC E186X proband is typical of
human lipodystrophy (Garg, 2004). Discrepancies between
mouse and human phenotypes have been reported previously:
PPARG P467L and other ligand binding domain variants
consistently cause lipodystrophy and severe insulin resistance
in humans (Semple et al, 2006), whereas mice with the
equivalent Pparg P465L mutation are neither lipodystrophic nor
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Figure 2. Adipose tissue histology from the E186X CIDEC proband.
A. Light microscopy of a subcutaneous adipose tissue biopsy taken from the
lateral chest wall (axillary region) of the CIDEC E186X proband showing
several perilipin positive multilocular adipocytes (left). Perilipin staining
in control adipose tissue is seen in the right hand panel. Note that vessels
and granulocytes (arrow) inside the vessels are negative to perilipin.
Mean unilocular adipocyte cross sectional area is 4799.8 451.04mm
2
corresponding to a mean adipocyte weight of 0.22 0.00mg lipid per cell
in the patient’s sample. In comparison, the mean adipocyte area in dorsal
subcutaneous adipose tissue from a BMI-matched person was
5379.84 702.07mm
2 and the mean adipocyte weight from the same
control was 0.27 0.01mg lipid per cell. Results are given as mean SE.
B. Light microscopy revealed a mixed cell population containing unilocular
(UL), multilocular (ML) and intermediate paucilocular (PL) adipocytes in
the proband’s biopsy. Mean SE cell size was estimated by analysing 21
cells of each type.
 p<0.05 compared with unilocular adipocytes.
C. Immunoreactivity for cytochrome c, a mitochondrial marker, is increased
focally (arrows) in some multilocular adipocytes from the E186X CIDEC
proband, but not in unilocular adipocytes. The ‘dot-like’ immunoreactivity
corresponds to mitochondria.
D. Electron micrograph (EM) showing multilocular lipid droplets in adipose
tissue from the proband with focally increased mitochondria (red arrows
point to the area containing mitochondria).
Scale bar length: panel A¼36.23mm; C¼14.32mm; D¼5mm.
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if this discrepancy indicates the existence of species-speciﬁc
differences in the global metabolic response to perturbations of
adipocyte biology.
In Fsp27 KO mice, all white adipocytes appeared to have
multilocular lipid droplets (Nishino et al, 2008; Toh et al, 2008),
whereas we observed adipocytes with unilocular and paucilo-
cular lipid droplets in addition to the multilocular cells (Fig 2A).
Until more is known about the function of CIDEC, we can only
speculate about the molecular origins of this ﬁnding. Although
our transfection studies suggest that the truncated protein fails
to increase lipid droplet size, it remains possible that it does
retain some in vivo activity (for instance, the CIDE-N domain
remains intact). The progressive increase in the size of
adipocytes with fewer and ultimately a single lipid droplet
compared to multilocular cells (Fig 2B) also suggests that lipid
droplets may eventually fuse to generate a single large droplet
despite ‘CIDEC deﬁciency’. CIDEA, another member of the CIDE
family of proteins, is predominantly expressed in brown, rather
than white, adipose tissue in mice, but is expressed in white
adipocytes in humans (Puri et al, 2008). It is therefore also
possiblethatCIDEA maycompensate,atleastinpart,fortheloss
of CIDEC function. We have sequenced the coding regions of
CIDEA in our patient and her family. She was heterozygous for
an arginine to tryptophan substitution at codon 5 (R5W) (data
not shown). This variant was also present in one of her half-
brothers, who was phenotypically normal, and in 16.7% of 108
SouthAmericancontrolalleles.ItislocatedinanN-terminallead
sequencebeforetheCIDE-Ndomainandhenceisnotexpectedto
alter the protein structure. These observations suggest that the
CIDEA variant is a common polymorphism and is unlikely to be
pathogenic but we cannot exclude the possibility that it might
contribute to the proband’s extreme phenotype.
The perception that converting white adipocytes into
thermogenic brown adipocytes could cause weight loss and
improve insulin sensitivity has prompted successful attempts
to do this in rodents. These efforts included both genetic
(Tsukiyama-Kohara et al, 2001) and pharmacological
approaches such as chronic treatment with a selective
b 3-adrenergic agonist (Himms-Hagen et al, 2000). In all cases,
UCP1 expression and mitochondrial mass were increased in
multilocular adipocytes. Although the limited amount of
available tissue meant that we could not formally assess
mitochondrial mass or function in WAT from the CIDEC E186X
proband, cytochrome c immunoreactivity and electron micro-
graphs suggested that mitochondrial mass was increased. The
absence of UCP1 immunostaining suggests that these cells are
not brown adipocytes. Nevertheless, are these multilocular
adipocytes likely to account for the increased RMR observed in
ourpatient?Itiscurrentlynotpossibletoaccuratelymeasurethe
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Figure 3. Cellular analysis of the impact of wild type and E186X truncated CIDEC
expression on lipid droplet size.
A. COS cells transfected for 24h.
B. 3T3L1 pre-adipocytes transfected for 32h with human wild type
GFP-CIDEC (WT, top row) and E186X truncated GFP-CIDEC (E186X, bottom
row) and cultured in a medium containing 20mM OA/BSA (oleic acid
conjugated to bovine serum albumin). Middle panel in the top row of each
panel shows increased oil red staining of neutral lipids in cells expressing
human wild type CIDEC. Overlay of the GFP and oil red stains indicate
localization of some wild type CIDEC to lipid droplets, whereas there is no
overlap of E186X GFP-CIDEC and oil red staining. Expression of GFP alone
has no effect on lipid droplet size in COS and 3T3lL1 adipocytes (Fig 4 of
Supporting Information). Scale bar: 10mm.
C. Quantitative morphometric analysis of lipid droplets in COS cells and
3T3-L1 pre-adipocytes transfected with human wild type (WT) GFP-CIDEC
or E186X truncated GFP-CIDEC (E186X) or GFP alone (GFP) for 24h. The
values represent a fold change (mean SE) of lipid droplet volume of
transfected cells as compared to untransfected cells in the same field.
 p<0.01 compared to WT.
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humans, but the mass speciﬁc contribution of fat to energy
expenditure is roughly 17kJ/kg/day, about one sixth of that of
lean mass (Nelson et al, 1992). To account for a 1.3kJ/min
elevation in resting energy expenditure relative to healthy
volunteers, fat associated energy expenditure would need to be
double that seen in healthy fat metabolism. Changes in oxygen
consumption of this magnitude were recorded in adipocytes
from the Fsp27 KO mouse (Nishino et al, 2008).
Limitationsofourstudyincludethelackofadditionalaffected
family members or other kindreds with loss of function variants
in CIDEC. The fact that we did not identify additional pathogenic
CIDEC mutations in 168 patients with unexplained lipodystro-
phy suggests that this is likely to be a rare cause of partial
lipodystrophy, much like AKT2 (see Supporting Information).
The proband’s mother is heterozygous for the CIDEC variant but
is clinically and biochemically normal, which is consistent with
the normal phenotype of Fsp27 heterozygous KO mice (Nishino
et al, 2008). The proband’s presentation with diabetic
ketoacidosis despite manifesting acanthosis nigricans and high
plasma C-peptide levels is intriguing and suggests that lipolytic
regulationmaybeimpaired.Thepresenceofhighfastingplasma
freefattyacidlevels(1048mmol/l(280–920))andelevatedurine
glycerol levels(713mmol/mol creatinine(17–183)) isinkeeping
with this possibility. Plasma free fatty acids were normal in
Fsp27 KO mice, although one study suggested that elevated
intracellular fatty acid levels may be responsible for inducing
mitochondrial biogenesis and fat oxidation (Nishino et al, 2008;
Puri & Czech, 2008; Toh et al, 2008).
In summary, we report a novel autosomal recessive cause of
partial lipodystrophy. The clinical phenotype is similar to that
caused by mutations in LMNA, PPARG and AKT2, all of which
manifest striking lower limb and femorogluteal lipodystrophy,
fatty liver, dyslipidaemia and insulin-resistance. Together
with observations made in cultured cells and Fsp27 KO
mice, our observations also suggest that CIDEC is required
for optimal energy storage in ‘unilocular adipocytes’ in humans,
although we recognize that this statement is tempered by the
fact that it is currently based on observations in a single small
kindred.
METHODS
Genetic and phenotypic studies
The study was conducted in accordance with the principles of the
Declaration of Helsinki and was approved by the UK National Health
Service Research Ethics Committee. Each participant, or a parent in
the case of minors, provided written informed consent; minors
provided oral consent.
Genomic DNA was isolated from peripheral-blood leukocytes. After
excluding mutations in the coding regions and splice junctions of
LMNA, PPARG, ZMPSTE24 and AKT2, the coding regions and splice
junctions of CIDEC were amplified by PCR and sequenced (primer
sequences available upon request).
Insulin sensitivity was calculated using HOMA %S (homeostasis
model assessment) (Levy et al, 1998). Body composition was
measured by whole-body DXA and fat distribution was assessed using
a 1.5T MR scanner to acquire T1-weighted water suppressed images.
RMR was measured using a ventilated canopy indirect calorimeter
after an overnight fasting. Subcutaneous fat was studied using light
microscopy, immunohistochemistry, and EM (see Supporting Informa-
tion for details).
Cellular functional analysis
3T3-L1 pre-adipocytes and COS cells were cultured and differentiated
in standard conditions (Puri et al, 2008). For cells incubated with fatty
acids, 20mM oleic acid/BSA mixture was added to the medium 8h
after transfection. CIDEC plasmid DNA was procured from Open
Biosystems. For full length CIDEC, PCR was performed by using a 50-
linker with a BglII restriction site and a 30-linker containing an EcoRI
site. For truncated CIDEC (E186X), PCR was performed by using the
same 50-linker and a 30-linker containing a HindIII site. Following a
restriction digest, purified PCR fragments were cloned into pEGFPC1
vector (Clontech, USA). GFP-CIDEC cDNA (5mg) was transfected into
COS cells using the Lipofectamine Plus Reagent (GIBCO Life
Technologies, Rockville, Maryland). Pre-adipocytes and adipocytes
were electroporated with 6mg cDNA (200,000cells/200ml PBS) in a
0.4cm cuvette at 180V and 950mF with a time constant of 25ms on
a Bio-Rad Gene Pulser II system. After transfection, the cells were
cultured for 24–48h before fixing and staining with oil red. Oil-red-O
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Figure 4. Mislocalization of E186X CIDEC in adipocytes.
A. Day six differentiated 3T3L1 adipocytes transfected with human wild type
GFP-CIDEC (WT, top row) and E186X truncated GFP-CIDEC (E186X, bottom
row). Overlay (right panels) of the GFP (left panels) and oil red stains
(middle panels) suggest that most WT CIDEC surrounds lipid droplets
whereas the mutant protein is almost entirely cytosolic. Scale bar: 10mm.
B. Co-localization analysis of GFP florescence with oil red-labelled lipid
droplets in each Z-section of a transfected adipocyte. The data are
from 8–10 adipocytes in each condition from three independent
experiments.
  p<0.0001 compared to WT.
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microscopy were undertaken as described previously (Puri et al, 2008).
Measurements of the total volume of lipid droplets per cell (10–
25 cells in each case) were based on at least three independent
experiments. Association of full length or truncated CIDEC with lipid
droplets in adipocytes was assessed using Metamorph software by
performing a co-localization analysis of GFP florescence with Oil-red-
O labelled lipid droplets in each Z-section of a transfected cell; these
results were then averaged to calculate the overall co-localization in a
given cell. The data are from 8–10 adipocytes in each condition from
three independent experiments.
Statistical analysis
Quantitative data are presented as mean SE. Two-tailed Student’s t-
tests or one-way ANOVA with post hoc Bonferroni analyses were
performed on data at a minimum p<0.05 threshold.
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FPLD due to a homozygous nonsense CIDEC mutation
The paper explained
PROBLEM:
Lipodystrophy is a rare disease characterized by a partial or
complete lack of adipose tissue. Paradoxically, both ‘too much’
(obesity) and ‘too little’ (lipodystrophy) fat lead to adipose tissue
dysfunction, ectopic lipid accumulation, insulin resistance and
diabetes.
Withinthelastdecade,investigatorshaveidentifiedmutationsin
seven different genes in patients with lipodystrophy. In this
study, we focused on a novel subtype of partial lipodystrophy.
RESULTS:
Wereporttheidentificationofahomozygousnonsensemutation
inCIDECinapatientwithpartiallipodystrophy,fattyliver,severe
insulin resistance, dyslipidaemia and diabetes. Histological
studiesofresidualadiposetissuefromthepatientrevealedwhite
adipocytes with multiloculated lipid droplets and excess
mitochondria.Functionalstudiesofthemutantproteinindicated
that it fails to increase the lipid droplet size and, contrary to the
wild type protein, it does not localize around lipid droplets in
transfected cells.
IMPACT:
The results add the CIDEC gene to the list of genes whose
mutation is associated with lipodystrophy. CIDEC is a recently
identified lipid droplet protein whose function remains
incompletely understood. CIDEC (Fsp27) null mice manifest low
fat mass and multilocular adipocytes with excess mitochondria,
but in contrast to our patient, these mice are insulin sensitive.
Together, these studies suggest that CIDEC is required for
unilocular lipid droplet formation and optimal lipid storage in
white adipose tissue. The differences between the human and
mouse phenotypes raise intriguing questions about interspecies
differences in adipose tissue metabolism.
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